Korro Bio, Inc. - Common Stock (KRRO)

Korro Bio is lagging Wave Life Sciences. But an analyst says it could ultimately be the leader.

This strategic play will take time to pay off, but it could keep growth going.

Wednesday, Canada-based NanoVation Therapeutics announced a multi-year partnership with Novo Nordisk A/S (NYSE:NVO) to advance the ...

William Blair initiates coverage on Korro Bio highlighting its innovative RNA editing platform, ADAR-based OPERA. The analyst rates the stock Outperform, noting its potential in treating alpha-1 antitrypsin deficiency.

KRRO stock results show that Korro Bio missed analyst estimates for earnings per share the second quarter of 2024.

KRRO stock results show that Korro Bio beat analyst estimates for earnings per share the fourth quarter of 2023.

KRRO stock results show that Korro Bio beat analyst estimates for earnings per share the first quarter of 2024.

U.S. stocks were lower, with the Dow Jones index dipping more than 500 points on Tuesday.

H.C. Wainwright initiated coverage on Korro Bio Inc (NASDAQ: KRRO), a biotech company developing genetic medicines focused on editing ribonucleic acid (RNA) to treat various diseases.

These stocks are coming off a banner month, but what about the road ahead?

U.S. stocks traded higher, with the Dow Jones gaining over 50 points on Monday. Here are some big stocks recording losses in today’s session.